FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The OPUS study showed cetuximab plus FOLFOX4 improved outcomes in KRAS exon 2 wild-type metastatic colorectal cancer (mCRC).
• However, cetuximab addition was detrimental in patients with KRAS exon 2 mutations.
• This study investigated outcomes based on extended RAS testing.

Purpose of the Study:

• To evaluate the efficacy of cetuximab plus FOLFOX4 in mCRC patients based on extended RAS (KRAS and NRAS) mutation status.
• To identify patient subgroups who benefit from or are harmed by cetuximab treatment.

Main Methods:

• Reanalysis of tumor samples from the OPUS study for additional KRAS and NRAS mutations using BEAMing technology.
• RAS status was defined using a 5% mutant/wild-type sequence cutoff, with an additional analysis at the 0.1% technical limit.

Main Results:

• Extended RAS testing identified mutations in 26% of evaluable patients.
• In the RAS wild-type subgroup (n=87), cetuximab plus FOLFOX4 significantly improved objective response (58% vs 29%; P=0.0084).
• Patients with any RAS mutation (KRAS or NRAS) showed a detrimental effect with cetuximab addition, while those with other RAS mutations showed no benefit.

Conclusions:

• Patients with RAS-mutant mCRC (including KRAS and NRAS exons 2-4 mutations) do not benefit from cetuximab plus FOLFOX4 and may experience harm.
• Restricting cetuximab to RAS wild-type mCRC patients can optimize treatment efficacy and maximize patient benefit.